TrialOpen forum infectious diseases2024

Dolutegravir/Lamivudine Efficacy and Safety Outcomes in People With HIV-1 With or Without Historical Resistance Results at Screening: 48-Week Pooled Analysis.

Stefan Scholten et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.